Have a feature idea you'd love to see implemented?
Let us know!
PRLD Prelude Therapeutics Inc
Price (delayed)
$1.55
Market cap
$85.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.8
Enterprise value
$71.62M
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective
Highlights
The EPS has increased by 23% year-on-year and by 4.3% since the previous quarter
The quick ratio has plunged by 54% YoY and by 32% from the previous quarter
The equity has declined by 30% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of PRLD
Market
Valuations
Earnings
Shares outstanding
55.02M
Market cap
$85.29M
Enterprise value
$71.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$129.85M
EBITDA
-$126.49M
Free cash flow
-$106.48M
Per share
Balance sheet
Liquidity
EPS
-$1.8
Free cash flow per share
-$1.41
Book value per share
$3.32
Revenue per share
$0
TBVPS
$2.96
Total assets
$224.29M
Total liabilities
$42.02M
Debt
$18.2M
Equity
$182.28M
Working capital
$159.38M
Debt to equity
0.1
Current ratio
7.83
Quick ratio
7.88
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-51.6%
Return on equity
-59.8%
Return on invested capital
-59.6%
Return on capital employed
-64.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRLD stock price
How has the Prelude Therapeutics stock price performed over time
Intraday
-5.49%
1 week
-19.27%
1 month
-29.55%
1 year
-26.54%
YTD
-63.7%
QTD
-25.12%
Financial performance
How have Prelude Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.27M
Net income
-$129.85M
Gross margin
N/A
Net margin
N/A
PRLD's operating income is down by 14% year-on-year and by 3.5% since the previous quarter
Prelude Therapeutics's net income has decreased by 11% YoY and by 3.4% QoQ
Growth
What is Prelude Therapeutics's growth rate over time
Valuation
What is Prelude Therapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 23% year-on-year and by 4.3% since the previous quarter
The stock's P/B is 84% below its 5-year quarterly average of 3.0 and 53% below its last 4 quarters average of 1.0
The equity has declined by 30% year-on-year and by 14% since the previous quarter
Efficiency
How efficient is Prelude Therapeutics business performance
PRLD's return on equity is down by 13% since the previous quarter and by 9% year-on-year
The ROA has contracted by 9% from the previous quarter and by 4% YoY
Prelude Therapeutics's ROIC has decreased by 9% from the previous quarter but it has increased by 7% YoY
Dividends
What is PRLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRLD.
Financial health
How did Prelude Therapeutics financials performed over time
PRLD's total liabilities has soared by 126% YoY and by 16% from the previous quarter
The current ratio has dropped by 54% year-on-year and by 33% since the previous quarter
The debt is 90% lower than the equity
The equity has declined by 30% year-on-year and by 14% since the previous quarter
PRLD's debt to equity is up by 25% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.